CD4+ CD56+ blastic tumor of the skin: Cytogenetic observations and further evidence of an origin from plasmocytoid dendritic cells

European Journal of Dermatology

Volumn 14, Issue 5, 2004, Pages 317-322

  Hallermann, C ^a   Middel, P ^a   Griesinger, F ^a   Gunawan, B ^a   Bertsch, H P ^a   Neumann, C ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

CD4; CD56; CGH; Plasmocytoid dendritic cells

Indexed keywords

CD123 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 3 RECEPTOR; PREDNISONE; RADIOSENSITIZING AGENT; VINCRISTINE;

AGED; ANAMNESIS; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; BLASTIC NATURAL KILLER CELL LYMPHOMA; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CELL LINEAGE; CHROMOSOME 13Q; CHROMOSOME 3P; CHROMOSOME 7Q; CHROMOSOME LOSS; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DENDRITIC CELL; FATALITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; LABORATORY TEST; LYMPHOMA; NATURAL KILLER CELL; PHENOTYPE; PLASMA CELL; PUVA; SKIN LYMPHOMA;

AGED; ANTIGENS, CD4; ANTIGENS, CD56; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DENDRITIC CELLS; DIAGNOSIS, DIFFERENTIAL; DOXORUBICIN; FATAL OUTCOME; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, NON-HODGKIN; PREDNISONE; SKIN NEOPLASMS; VINCRISTINE;

EID: 4544231060     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Feuillard J, Jacob M-C, Valensi F, et al. Clinical and biological features of CD4+CD56+ malignancies. Blood 2002; 99: 1550-63.
2. Dummer R, Potoczna N, Hoffner AC, et al. A primary cutaneous non-T, non-B CD4+, CD56+ lymphoma. Arch Dermatol 1996; 132: 550-3.
3. Petrella T, Dalac S, Maynadie M, et al. CD4+CD56+ cutaneous neoplasms: A distinct hematological entity? Am J Surg Pathol 1999; 23: 137-46.
4. Penven K, Macro M, Salaun V, et al. Skin manifestations in CD4+, CD56+ malignancies. Eur J Dermatol 2003; 13: 161-5.
5. Petrella T, Comeau M, Maynadie M, et al. Agranular Cd4+CD56+ hematodermic neoplasm' (Blastic NK-Cell Lymphoma) originates from a population of Cd56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002; 26: 852-02.
6. Jaffe ES, Harris NL, Stein H, et al. Warld Health Organization Classification of tumours. Pathology and genetics of tumours of haematapoetic and lymphoid tissues. Lyon: IARC Press; 2001.
7. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001; 97: 3210-7.
8. Kneba M, Bolz I, Linke B, et al. Characterization of clone-specific rearranged T-cell receptor gamma-chain genes in lymphomas and leucemias by the polymerase chain reaction and DNA sequencing. Blood 1994; 84: 574-81.
9. Reinhardt D, Langebrake C, Creutzig U, et al. Minimal residual disease in acute myeloid leukemia in children-standardization and evaluation of immunaphenotyping in the AML-BFM-98 study. Klin Padiatr 2002; 214: 179-87.
10. Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258: 818-21.
11. Hallermann C, Kaune KM, Siebert R, et al. Chromosomal aberration patterns differ in subtypes of primary cutaneous B-cell lymphomas. J Invest Dermatol 2004; in press.
12. Herling M, Teitell MA, Shen RR, et al. TCL1 Expression in plasmocytoid dendritic cells (CD2) and related CD4CD56 blastic tumors of skin. Blood 2003; 101: 5007-9.
13. Bagot M, Bouloc A, Charue D, et al. Do primary cutaneous non-T non-B CD4+CD56+ lymphomas belong to the myelo-monocytic lineage? J Invest Dermatol 1998; 111: 1242-4.
14. Grouard G, Rissoan MC, Filgueira L, et al. The enigmatic plasmocytoid T-cells develop into dendritic cells with interleucin (IL)-3 and CD40 ligand. J Exp Med 1997; 185: 1101-11.
15. Jacob MC, Chaperot L, Mossuz P, et al. CD4+CD56+ lineage negative malignancies: a new entity developed fram malignant early plasmocytoid dendritic cells. Haematologica 2003; 88: 941-55.
16. Khoury JD, Medeiros L, Manning J, et al. CD56(+)TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leucemia. Cancer 2002; 94: 2401-8.
17. Comeau MR, Van der Vuurst de Vries AR, Maliszewski CR, et al. CD123 bright plasmocytoid predendritic cells: Progenitors undergoing cell fate conversion? J Immunol 2002; 109: 75-83.
18. Leroux D, Mugneret F, Callanan M, et al. CD4+CD56+DC 2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogenetique Hematologique. Blood 2002; 99: 4154-9.
19. Chaganti RSK, Nanjangud G, Schmidt H, Teruya-Feldstein J. Recurrent chromosomal abnormalities in Non-Hodgkin's lymphoma: Biologic and clinical significance. Semin Hematol 2000; 37: 396-411.
20. Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood 1994; 84: 3253-60.
21. Mao X, Onadim Z, Price EA, et al. Genomic alterations in blastic natural killer/extranodal natural killer-like T cell lymphoma with cutaneous involvement. J Invest Dermatol 2003; 121: 618-27.